Latest Psivida Corp (PSDV) Headlines pSivida Co
Post# of 79
Posted On: 03/13/2014 12:52:46 PM
Latest Psivida Corp (PSDV) Headlines
pSivida Corp. Announces $7.0 Million Investment by RA Capital
Business Wire - Thu Mar 13, 8:46AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest approximately $7.0 million in a registered direct offering through the sale of a total of 1.7 million shares of the Company's common stock at a per share price of $4.11.
10-Q: PSIVIDA CORP.
Edgar Online - Wed Feb 12, 9:31AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
pSivida Announces ILUVIEN(R) for DME Accepted by National Health Service Scotland
Business Wire - Mon Feb 10, 8:05AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN(R) for use within the National Health Service (NHS) Scotland under a simple patient access scheme. ILUVIEN will be available in the NHS Scotland to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies in pseudophakic eyes (those that have undergone cataract surgery).
pSivida Corp. Reports Second Quarter 2014 Results
Business Wire - Fri Feb 07, 3:00PM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11
Business Wire - Thu Feb 06, 9:24AM CST
pSivida Corp. (NASDAQ SDV)(ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 16th Annual BioCEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York, Monday and Tuesday, February 10 and 11. Dr. Ashton will make his presentation on Tuesday, February 11 at 9:30 EST. A webcast of the presentation will be available at: http://www.veracast.com/webcasts/bio/ceoinves...464352.cfm or at the company's website: www.psivida.com. There will be a webcast replay available one hour after the conclusion of Dr. Ashton's presentation that day and it will be available until May 11, 2014.
Research and Markets: Commercial Construction in New Zealand to 2017: Market Forecast Report
Business Wire - Thu Feb 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfx4k6/commercial) has announced the addition of the "Commercial Construction in New Zealand to 2017: Market Forecast" report to their offering.
pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Thu Jan 30, 3:39PM CST
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market close on Friday, February 7, 2014, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
3 Stocks Under $10 Moving Higher
at The Street - Wed Jan 29, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Hot Stock: pSivida, Shares Gain 8.7% (PSDV)
Comtex SmarTrend(R) - Mon Jan 13, 10:16AM CST
pSivida (NASDAQ SDV) is one of today's best performing low-priced stocks, up 8.7% to $4.48 on 1.0x average daily volume. pSivida has traded 351,000 shares thus far today, vs. average volume of 340,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's -0.0%) and outperformed the S&P 500 (8.7% to the S&P's -0.0%) during today's trading.
pSivida Corp. Reports First Orders for ILUVIEN(R) Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance
Business Wire - Mon Jan 13, 6:13AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of ILUVIEN(R) to several U.K. National Health Service (NHS) facilities and the first NHS patient has received ILUVIEN for the treatment of chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
pSivida Corp. (PSDV) Jumps: Stock Up 32.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 6:51AM CST
pSivida Corp. was a big mover last session, as its shares rose roughly 32% on the day.
Update on pSivida's Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 2:30PM CST
pSivida announced that its partner Alimera Sciences has successfully conducted labeling discussions with the FDA for Iluvien for the treatment of Diabetic Macular Edema.
Opening Buzz: SolarCity Corp, 3D Systems Corporation, pSivida Corp, Alcatel Lucent SA
ACCESSWIRE - Thu Dec 19, 9:45AM CST
New York, December 19, 2013 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for SolarCity Corp (NASDAQ:SCTY), 3D Systems Corporation (NYSE
DD), pSivida Corp.(NASDAQ SDV), Alcatel Lucent SA (ADR) (NYSE:ALU).
pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN(R) for DME; Advisory Committee Meeting No Longer Necessary
Business Wire - Wed Dec 18, 3:32PM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling discussions with the U.S. Food and Drug Administration (FDA) for ILUVIEN(R) for Diabetic Macular Edema (DME) and, as a result, reported its agreement with the FDA that the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting to discuss ILUVIEN for DME was no longer necessary.
pSivida Corp - Value Drivers - The Road Forward for pSivida
ACCESSWIRE - Mon Dec 09, 10:38AM CST
pSivida Corp (NASDAQ SDV) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Dr. Paul Ashton. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Final Guidance from NICE for pSivida's Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 3:00PM CST
pSivida announced that the NICE has issued final guidance recommending Iluvien to treat pseudophakic patients with chronic DME.
pSivida Executives to Present at Two Upcoming Investor Conferences This Month
Business Wire - Wed Dec 04, 7:00AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor conferences:
pSivida Reports ILUVIEN(R) to Be Funded by UK's National Health Service for Treatment of Pseudophakic Chronic DME Patients Following Issuance of Final NICE Guidance
Business Wire - Mon Dec 02, 6:17AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013, the United Kingdom's National Institute for Health and Care Excellence (NICE) published final guidance recommending ILUVIEN(R) as a treatment option for pseudophakic patients (those who have had cataract surgery) with chronic Diabetic Macular Edema (DME) insufficiently responsive to available therapies, subject to a patient access scheme. NICE requires clinical commissioning groups, the National Health Service England and local public health authorities to comply with the recommendation in the final guidance within three months of its date of publication.
pSivida Corp. Announces $7.0 Million Investment by RA Capital
Business Wire - Thu Mar 13, 8:46AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that RA Capital has entered into a securities purchase agreement with the Company to invest approximately $7.0 million in a registered direct offering through the sale of a total of 1.7 million shares of the Company's common stock at a per share price of $4.11. 10-Q: PSIVIDA CORP.
Edgar Online - Wed Feb 12, 9:31AM CST
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
pSivida Announces ILUVIEN(R) for DME Accepted by National Health Service Scotland
Business Wire - Mon Feb 10, 8:05AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN(R) for use within the National Health Service (NHS) Scotland under a simple patient access scheme. ILUVIEN will be available in the NHS Scotland to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies in pseudophakic eyes (those that have undergone cataract surgery).
pSivida Corp. Reports Second Quarter 2014 Results
Business Wire - Fri Feb 07, 3:00PM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its second quarter ended December 31, 2013.
pSivida CEO to Present at 16th Annual BioCEO & Investor Conference February 11
Business Wire - Thu Feb 06, 9:24AM CST
pSivida Corp. (NASDAQ
SDV)(ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, President and CEO, will present at the 16th Annual BioCEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York, Monday and Tuesday, February 10 and 11. Dr. Ashton will make his presentation on Tuesday, February 11 at 9:30 EST. A webcast of the presentation will be available at: http://www.veracast.com/webcasts/bio/ceoinves...464352.cfm or at the company's website: www.psivida.com. There will be a webcast replay available one hour after the conclusion of Dr. Ashton's presentation that day and it will be available until May 11, 2014. Research and Markets: Commercial Construction in New Zealand to 2017: Market Forecast Report
Business Wire - Thu Feb 06, 4:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfx4k6/commercial) has announced the addition of the "Commercial Construction in New Zealand to 2017: Market Forecast" report to their offering.
pSivida Corp Announces Second Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Thu Jan 30, 3:39PM CST
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the second quarter of fiscal year 2014 will be released after the market close on Friday, February 7, 2014, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. 3 Stocks Under $10 Moving Higher
at The Street - Wed Jan 29, 6:00AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Hot Stock: pSivida, Shares Gain 8.7% (PSDV)
Comtex SmarTrend(R) - Mon Jan 13, 10:16AM CST
pSivida (NASDAQ
SDV) is one of today's best performing low-priced stocks, up 8.7% to $4.48 on 1.0x average daily volume. pSivida has traded 351,000 shares thus far today, vs. average volume of 340,000 shares per day. The stock has outperformed the Dow (8.7% to the Dow's -0.0%) and outperformed the S&P 500 (8.7% to the S&P's -0.0%) during today's trading. pSivida Corp. Reports First Orders for ILUVIEN(R) Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance
Business Wire - Mon Jan 13, 6:13AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of ILUVIEN(R) to several U.K. National Health Service (NHS) facilities and the first NHS patient has received ILUVIEN for the treatment of chronic diabetic macular edema (DME) insufficiently responsive to available therapies.
Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
pSivida Corp. (PSDV) Jumps: Stock Up 32.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 6:51AM CST
pSivida Corp. was a big mover last session, as its shares rose roughly 32% on the day.
Update on pSivida's Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 2:30PM CST
pSivida announced that its partner Alimera Sciences has successfully conducted labeling discussions with the FDA for Iluvien for the treatment of Diabetic Macular Edema.
Opening Buzz: SolarCity Corp, 3D Systems Corporation, pSivida Corp, Alcatel Lucent SA
ACCESSWIRE - Thu Dec 19, 9:45AM CST
New York, December 19, 2013 / Accesswire / - Market Buzz Report, which provides live alerts on penny stocks, issues critical stocks analysis for SolarCity Corp (NASDAQ:SCTY), 3D Systems Corporation (NYSE
DD), pSivida Corp.(NASDAQ SDV), Alcatel Lucent SA (ADR) (NYSE:ALU). pSivida Corp. Reports FDA Labeling Discussions for ILUVIEN(R) for DME; Advisory Committee Meeting No Longer Necessary
Business Wire - Wed Dec 18, 3:32PM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has entered into labeling discussions with the U.S. Food and Drug Administration (FDA) for ILUVIEN(R) for Diabetic Macular Edema (DME) and, as a result, reported its agreement with the FDA that the January 2014 Dermatologic and Ophthalmic Advisory Committee meeting to discuss ILUVIEN for DME was no longer necessary.
pSivida Corp - Value Drivers - The Road Forward for pSivida
ACCESSWIRE - Mon Dec 09, 10:38AM CST
pSivida Corp (NASDAQ
SDV) today published a new blog post on The Chairman's Blog, written by the company's President and CEO, Dr. Paul Ashton. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends. Final Guidance from NICE for pSivida's Iluvien - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 3:00PM CST
pSivida announced that the NICE has issued final guidance recommending Iluvien to treat pseudophakic patients with chronic DME.
pSivida Executives to Present at Two Upcoming Investor Conferences This Month
Business Wire - Wed Dec 04, 7:00AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that company management will present at two upcoming investor conferences:
pSivida Reports ILUVIEN(R) to Be Funded by UK's National Health Service for Treatment of Pseudophakic Chronic DME Patients Following Issuance of Final NICE Guidance
Business Wire - Mon Dec 02, 6:17AM CST
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that on November 27, 2013, the United Kingdom's National Institute for Health and Care Excellence (NICE) published final guidance recommending ILUVIEN(R) as a treatment option for pseudophakic patients (those who have had cataract surgery) with chronic Diabetic Macular Edema (DME) insufficiently responsive to available therapies, subject to a patient access scheme. NICE requires clinical commissioning groups, the National Health Service England and local public health authorities to comply with the recommendation in the final guidance within three months of its date of publication.
(0)
(0)